93 results
Page 4 of 5
8-K
EX-99.1
uog0mr
8 Nov 19
CORRECTION – Aravive Reports Third Quarter 2019 Financial Results and Provides Recent Corporate Updates
2:33pm
8-K
EX-99.1
u7qa236veotcz 19wxcx
7 Nov 19
Aravive Reports Third Quarter 2019 Financial Results and Provides Recent Corporate Updates
4:10pm
8-K
EX-99.1
f7ere0
3 Oct 19
Other Events
7:15am
8-K
EX-99.2
ot6oyo
27 Sep 19
Other Events
10:15am
8-K
EX-99.1
oult 4h0wo
27 Sep 19
Other Events
10:15am
8-K
EX-99.1
lwv4yiepymsaabqsa
12 Aug 19
Other Events
7:05am
8-K
EX-99.1
8ylrksaz2lhmj4d5cutj
8 Aug 19
Aravive Announces Executive Management Transition Plan
5:06pm
8-K
EX-99.1
x4qwm2 6d
31 Jul 19
Aravive Reports Preliminary Results ofAVB-500 from the First Cohort of the Phase 1b/Phase 2 Recurrent Platinum Resistant Ovarian Cancer Trial
7:15am
8-K
EX-99.1
z7ncns6h0go 162t
8 Jul 19
Other Events
7:16am
8-K
bvot3lyeb24y ny07ma
31 May 19
Termination of a Material Definitive Agreement
4:16pm
8-K
EX-99.1
58jgwaod0810fm
8 May 19
Aravive Reports First Quarter 2019 Financial Results and Provides Recent Corporate Updates
4:15pm
8-K
EX-99.1
ssfdt1qnql0o388x3
5 Feb 19
Regulation FD Disclosure
7:01am
8-K
EX-99.1
mzwuk v1212
13 Nov 18
Aravive Presents Detailed Results of Phase 1 Clinical Trial of AVB-S6-500 at the 2018 EORTC-NCI-AACR Symposium
7:10am
8-K
yxys086remm
13 Nov 18
Aravive Presents Detailed Results of Phase 1 Clinical Trial of AVB-S6-500 at the 2018 EORTC-NCI-AACR Symposium
7:10am
8-K
EX-99.1
awsrzlfoji
6 Nov 18
Aravive Reports Third Quarter 2018 Financial Results and Provides Company Updates
4:20pm
8-K
EX-99.1
wkxz5oct7db t4oo2
30 Oct 18
Regulation FD Disclosure
6:16am